Movatterモバイル変換

Jump to content

linezolid(Q411377)

From Wikidata

chemical compound

U-100766
Zyvox
N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
Linezolid
Linezolide
Linezolidum

Language	Label	Description	Also known as
default for all languages	No label defined
English	linezolid	chemical compound	U-100766 Zyvox N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide Linezolid Linezolide Linezolidum

Statements

type of chemical entity

0 references

1 reference

27 February 2018

1 reference

Linezolid(English)

language of work or name

publication date

17 November 2015

chemical structure

Linezolid.svg
385 × 195; 15 KB

0 references

337.144dalton

1 reference

language of work or name

linezolid(English)

19 October 2016

stereoisomer of

acetamide, n-[[(5r)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-

1 reference

based on heuristic

inferred from InChIKey

chemical formula

C₁₆H₂₀FN₃O₄

1 reference

language of work or name

linezolid(English)

19 November 2016

canonical SMILES

CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F

1 reference

language of work or name

linezolid(English)

19 November 2016

isomeric SMILES

CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F

1 reference

language of work or name

linezolid(English)

19 November 2016

active ingredient in

1 reference

14 February 2018

World Health Organisation international non-proprietary name

linezolid(English)

1 reference

language of work or name

linezolid(English)

19 October 2016

medical condition treated

bacterial pneumonia

1 reference

language of work or name

13 December 2016

staphylococcal infection

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

pulmonary tuberculosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

urinary tract infection

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

significant drug interaction

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

methyl (S)-phenyl[(S)-piperidin-2-yl]acetate

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+)-pseudoephedrine

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

procedural hypertension

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+)-pseudoephedrine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+)-pseudoephedrine

hypertensive crisis

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+)-pseudoephedrine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+)-pseudoephedrine

headache disorder

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

methyl (S)-phenyl[(S)-piperidin-2-yl]acetate

muscle stiffness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

methyl (S)-phenyl[(S)-piperidin-2-yl]acetate

hypertensive crisis

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

methyl (S)-phenyl[(S)-piperidin-2-yl]acetate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

methyl (S)-phenyl[(S)-piperidin-2-yl]acetate

headache disorder

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

toxic encephalopathy

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

muscle stiffness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

hypertensive crisis

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

headache disorder

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

muscle stiffness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

hypertensive crisis

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

headache disorder

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pregnancy category

Australian pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category A

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Linezolid

6 June 2019

1 reference

https://www.pfizer.com/products/product-list

subject has role

protein synthesis inhibitor

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

15 March 2018

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

essential medicine

0 references

1 reference

‎WHO Aware Classification

1 reference

2023 ‎AWaRe classification‎

138±1United States dollar

1 reference

http://www.drugs.com/price-guide/linezolid

Commons category

Linezolid

0 references

Identifiers

InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1

1 reference

language of work or name

linezolid(English)

19 November 2016

TYZROVQLWOKYKF-ZDUSSCGKSA-N

2 references

language of work or name

linezolid(English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

linezolid(English)

19 November 2016

TYZROVQLWOKYKF-ZDUSSCGKSA-N

CAS Common Chemistry

8 April 2021

https://commonchemistry.cas.org/detail?cas_rn=165800-03-3

1 reference

language of work or name

Linezolid(English)

19 November 2016

2 references

language of work or name

linezolid(English)

19 November 2016

matched by identifier from

TYZROVQLWOKYKF-ZDUSSCGKSA-N

Reaxys registry number

7496939

1 reference

language of work or name

linezolid(English)

19 October 2016

mapping relation type

2 references

language of work or name

LINEZOLID(English)

19 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1

1 reference

language of work or name

LINEZOLID(English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

TYZROVQLWOKYKF-ZDUSSCGKSA-N

UniChem compound ID

1 reference

MassBank accession ID

MSBNK-Eawag-EQ329101

0 references

MSBNK-Eawag-EQ329102

0 references

MSBNK-Eawag-EQ329103

0 references

MSBNK-Eawag-EQ329104

0 references

MSBNK-Eawag-EQ329105

0 references

MSBNK-Eawag-EQ329106

0 references

splash10-000j-0396000000-959c643931df034e05fc

0 references

splash10-000b-0940000000-066fc762e228726946fb

0 references

splash10-0292-0900000000-99847141a31b0134dcfa

0 references

splash10-000j-0900000000-7cf676c358a3890ab460

0 references

splash10-000j-0900000000-fdccf108eb9fcb8a102d

0 references

splash10-000i-1649000000-a1dedd5c256e9f3bfa4f

0 references

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

LINEZOLID(English)

10 May 2021

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

TYZROVQLWOKYKF-ZDUSSCGKSA-N

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(S)-N-((3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide(English)

CAS no.: 165800-03-3(English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(S)-N-((3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide(English)

CAS no.: 165800-03-3(English)

1 reference

language of work or name

Linezolid(English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

5 February 2021

MeSH descriptor ID

subject named as

Linezolid

0 references

D02.065.064.463

0 references

D02.241.081.018.110.525

0 references

D03.383.129.462.600.550

0 references

1 reference

Global Substance Registration System

language of work or name

linezolid(English)

19 November 2016

1 reference

matched by identifier from

TYZROVQLWOKYKF-ZDUSSCGKSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

TYZROVQLWOKYKF-ZDUSSCGKSA-N

2 references

Global Substance Registration System

language of work or name

linezolid(English)

19 November 2016

matched by identifier from

TYZROVQLWOKYKF-ZDUSSCGKSA-N

MedlinePlus drug identifier

route of administration

oral administration

0 references

route of administration

intravenous injection

0 references

PatientsLikeMe treatment ID

0 references

NIAID ChemDB ID

1 reference

imported from Wikimedia project

English Wikipedia

1 reference

Global Substance Registration System

language of work or name

linezolid(English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

linezolid(English)

19 October 2016

0 references

1 reference

6 April 2020

0 references

electronic Essential Medicines List medicine ID

0 references

Encyclopædia Britannica Online ID

topic/linezolid

subject named as

linezolid

reason for deprecated rank

withdrawn identifier value

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

1 reference

9 July 2020

Microsoft Academic ID

0 references

NCI Drug Dictionary ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

PDB structure ID

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3CPW(English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4K7Q(English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3DLL(English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4WFA(English)

19 October 2016

1 reference

1 reference

Global Substance Registration System

language of work or name

linezolid(English)

19 November 2016

1 reference

based on heuristic

inferred by common MeSH mappings on source and on Wikidata

25 May 2023

0 references

WikiProjectMed ID

0 references

Sitelinks

Wikipedia(34 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswikiCategory:Linezolid

Retrieved from "https://www.wikidata.org/w/index.php?title=Q411377&oldid=2329852320"

[8]ページ先頭

©2009-2025 Movatter.jp